|
Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe
|
14 September 2011 |
|
€1 Million Awarded to Winning Projects
|
30 August 2011 |
|
Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology
|
19 August 2011 |
|
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition
|
11 July 2011 |
|
Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"
|
23 June 2011 |
|
FDA approves linagliptin tablets for the treatment of type 2 diabetes
|
05 May 2011 |
|
Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled
|
12 April 2011 |
|
Boehringer Ingelheim's lead hepatitis C compound moves into phase III
|
04 April 2011 |
|
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
|
16 March 2011 |
|
Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement
|
15 February 2011 |
|
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement
|
13 February 2011 |
|
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance
|
16 January 2011 |
|
LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients
|
09 December 2010 |
|
Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
|
16 November 2010 |
|
Collaboration of Boehringer Ingelheim and VTU Technology
|
11 November 2010 |
|
US FDA Approves Pradaxa® (dabigatran etexilate)
|
22 October 2010 |
|
Afatinib (BIBW 2992) triples progression free survival in phase III study in lung cancer patients
|
12 October 2010 |
|
Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer
|
20 September 2010 |
|
Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"
|
27 August 2010 |
|
Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients
|
15 June 2010 |